The current review delves into the molecular mechanisms of PD-1/PD-L1 blockade resistance, emphasizing the synergistic anti-tumor effects of anti-PD-1/PD-L1 combined with other ICBs, so as to provide evidence for improving the benefits of ICBs in cancers. The gene discussed is CD274; the disease is cancer.